Dexcom
Dexcom, Inc., a leading player in the diabetes care industry, is headquartered in the United States. Founded in 1999, the company has pioneered continuous glucose monitoring (CGM) technology, significantly enhancing diabetes management for patients worldwide. With a strong presence in North America, Europe, and Asia, Dexcom focuses on developing innovative solutions that empower individuals to take control of their health. The company's flagship products, including the Dexcom G6 and G7 CGM systems, offer real-time glucose monitoring with exceptional accuracy and ease of use. These devices are distinguished by their ability to provide users with actionable insights, helping to prevent hypoglycaemic events and improve overall glycaemic control. Dexcom's commitment to innovation has solidified its position as a market leader, recognised for its contributions to diabetes management and patient care.
DitchCarbon Score
How does Dexcom's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dexcom's score of 40 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dexcom's reported carbon emissions
In 2023, Dexcom, Inc., headquartered in the United States, reported total carbon emissions of approximately 34,000,000 kg CO2e across all scopes. This includes 6,652,000 kg CO2e from Scope 1 emissions, primarily from mobile and stationary combustion, and 25,291,000 kg CO2e from Scope 2 emissions, calculated on a market-based approach. Scope 3 emissions were significantly higher, totalling about 325,942,000 kg CO2e, with major contributions from purchased goods and services, upstream transportation, and employee commuting. Comparatively, in 2022, Dexcom's total emissions were about 15,000,000 kg CO2e for Scope 1 and 13,614,000 kg CO2e for Scope 2, indicating a substantial increase in emissions in 2023. The company has disclosed emissions data for all three scopes, demonstrating a commitment to transparency in its environmental impact. While Dexcom has made near-term commitments to reduce emissions, specific reduction targets have not been established, and previous commitments have expired. The company is currently not committed to a net-zero target. This lack of long-term reduction goals may impact its sustainability profile within the healthcare equipment and supplies sector. Overall, Dexcom's emissions data reflects a significant environmental footprint, particularly in Scope 3 emissions, which are often the most challenging to manage. The company’s ongoing efforts and future commitments will be crucial in addressing its climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 2,044,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,371,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 1,257,000 | 0,000,000 | 0,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dexcom is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
